Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Roswell Park Cancer Institute National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00560495 |
RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
Condition | Intervention | Phase |
---|---|---|
Lung Cancer |
Drug: Tc 99m sestamibi Drug: ammonium tetrathiomolybdate Procedure: immunoenzyme technique Procedure: laboratory biomarker analysis Procedure: radiation therapy |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | The Combination of Radiotherapy With the Anti-Angiogenic Agent Tetrathiomolybdate (TM) in the Treatment of Stage I-IIIB Non-Small Cell Lung Cancer (NSCLC): A Phase I Study |
Estimated Enrollment: | 30 |
Study Start Date: | May 2007 |
Estimated Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE:
After completion of study therapy, patients are followed every 3 months for up to 2 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) meeting the following criteria:
Squamous, large cell undifferentiated, or adenocarcinoma
Mediastinal lymph nodes must be evaluated by either mediastinoscopy or by PET scan, unless definitive CT-positive mediastinal disease is noted
PATIENT CHARACTERISTICS:
Prior malignancy allowed if disease free for ≥ 5 years
PRIOR CONCURRENT THERAPY:
United States, New York | |
Roswell Park Cancer Institute | Recruiting |
Buffalo, New York, United States, 14263-0001 | |
Contact: Clinical Trials Office - Roswell Park Cancer Institute 877-275-7724 |
Principal Investigator: | Mohammad K. Khan, MD, PhD | Roswell Park Cancer Institute |
Study ID Numbers: | CDR0000574135, RPCI-EPR-38104 |
Study First Received: | November 16, 2007 |
Last Updated: | December 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00560495 |
Health Authority: | Unspecified |
stage I non-small cell lung cancer stage II non-small cell lung cancer stage IIIA non-small cell lung cancer stage IIIB non-small cell lung cancer |
adenocarcinoma of the lung adenosquamous cell lung cancer large cell lung cancer squamous cell lung cancer |
Tetrathiomolybdate Thoracic Neoplasms Non-small cell lung cancer Adenocarcinoma of lung Respiratory Tract Diseases Lung Neoplasms |
Lung Diseases Molybdenum Adenocarcinoma Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Trace Elements Enzyme Inhibitors Angiogenesis Inhibitors |
Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Micronutrients Chelating Agents Angiogenesis Modulating Agents Growth Inhibitors |